Buy high-quality intermediate from China manufacturer

The product is Ethyl 1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate, a fused bicyclic heterocycle that marries a tetrahydropyran ring with a pyrazole core and carries an ethyl ester at the 3‑position. The pyran oxygen and the two pyrazole nitrogen atoms create a hydrogen‑bond‑donor/acceptor‑rich surface, while the saturated pyran ring adds modest conformational mobility and an additional vector for substitution. The ethyl ester serves both as a polarity modulator and a latent handle for further derivatization into amides, acids, or alcohols. This unique scaffold has proven valuable in the design of biologically active molecules where fused pyrazole oxygen heterocycles are needed to fine‑tune pharmacokinetic and potency profiles.

The product is 2-(Cyclohept-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, a cyclic boronic ester featuring a seven-membered cycloheptene ring directly attached to a pinacol-stabilized boron center. The cyclohept-1-en-1-yl fragment provides an sp²-hybridized carbon–boron bond embedded within a somewhat flexible yet sterically defined cyclic olefin, while the pinacol dioxaborolane moiety imparts crystallinity, ease of handling, and controlled reactivity. This combination delivers a reagent that smoothly undergoes palladium-catalyzed Suzuki-Miyaura cross-coupling, enabling the direct introduction of a functionalized cycloheptene motif into complex molecular architectures without disrupting the integrity of the fragile seven-membered ring.

The product is 2-Methyl-L-proline Methyl ester hydrochloride, the hydrochloride salt of (S)‑2‑methylproline methyl ester, a conformationally constrained, chiral cyclic α‑amino acid derivative. The five‑membered pyrrolidine ring carries a quaternary α‑carbon with a methyl group, effectively locking the backbone φ and ψ torsion angles when incorporated into peptides. The methyl ester protects the carboxylic acid, and the hydrochloride salt protonates the secondary amine, rendering it a stable, crystalline solid. This compound is the key building block for introducing α‑methyl‑L‑proline into peptidomimetic drugs, where the quaternary center enhances metabolic stability and conformational rigidity.

The product is Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]-, a chiral epoxide intermediate featuring a protected 2‑benzyloxyphenyl core with a formamide substituent and a terminal (2R)‑oxirane ring. The epoxide provides a highly electrophilic, ring‑strained handle for regioselective nucleophilic opening, while the formamido group acts as a latent primary amine and a directing moiety for hydrogen bonding. The benzyl ether serves as a robust phenol protecting group that can be cleanly removed by hydrogenolysis at the end of the synthetic sequence. This orthogonal set of functional groups on a single aromatic ring makes it the definitive advanced chiral intermediate for constructing β‑amino alcohol pharmacophores with precise stereochemistry.

The product is Arformoterol tartrate, the single‑isomer (R,R)‑enantiomer of formoterol formulated as a 1:1 salt with L‑(+)‑tartaric acid, a long‑acting β₂‑adrenergic receptor agonist (LABA) approved for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease (COPD). Its structure comprises a formamido‑substituted phenylethanolamine core with a 4‑methoxyphenyl‑isopropyl side chain, where both the benzylic alcohol and the amine α‑methyl carbon bear the (R)‑configuration. The tartrate counterion confers aqueous solubility suitable for nebulized inhalation, while the (R,R)‑stereochemistry is responsible for the therapeutic bronchodilatory effect with a duration of action exceeding 12 hours.

The product is (2S)-HYDROXY(PHENYL)ACETIC ACID (2R)-N-BENZYL-1-(4-METHOXYPHENYL)PROPAN-2-AMINE (1:1) (SALT), a pre‑formed diastereomeric salt that combines the resolving agent (S)‑mandelic acid with the desired (2R)‑enantiomer of the key formoterol amine side chain. The salt simultaneously locks in the absolute configuration of the amine while providing a crystalline, storage‑stable, and non‑hygroscopic solid that is far more convenient to handle and quantify than the oily free base. This single compound represents the purified product of the classical resolution process, offering pharmaceutical manufacturers a ready‑to‑use, chirally pure building block that eliminates the need for in‑house resolution and chiral analysis.